Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapport TherapeuticsRAPP -0.11%14 EV-to-OCF is -18.77 as of Jul. 23, 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Rapport Therapeutics ranks better than 80.72% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Rapport Therapeutics's Enterprise Value is $1,507.12 Mil.
Rapport Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-80.30 Mil. Therefore, Rapport Therapeutics's EV-to-OCF for today is -18.77.
The historical rank and industry rank for Rapport Therapeutics's EV-to-OCF or its related term are showing as below:
RAPP'
s EV-to-OCF Range Over the Past 10 Years
Min: -19.27 Med: -16.57 Max: -13.95
Current: -18.77
During the past 4 years, the highest EV-to-OCF of Rapport Therapeutics was -13.95. The lowest was -19.27. And the median was -16.57.
RAPP's EV-to-OCF is ranked better than 80.72% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs RAPP: -18.77
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rapport Therapeutics (NAS:RAPP) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rapport Therapeutics's PE Ratio (TTM) for today is calculated as:
Rapport Therapeutics's share price for today is $41.255.
Rapport Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Rapport Therapeutics EV-to-OCF Related Terms
Rapport Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rapport Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's EV-to-OCF falls into.
Rapport Therapeutics's current Enterprise Value is $1,507.12 Mil.
Rapport Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-80.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (RAPP) has a EV-to-OCF of -18.77 as of Jul. 23, 2026. According to the industry distribution chart, Rapport Therapeutics ranks #272 out of 1411 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Rapport Therapeutics' EV-to-OCF too high?
Rapport Therapeutics' current EV-to-OCF is -18.77. Based on the distribution chart, Rapport Therapeutics ranks #272 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' EV-to-OCF compare to SION and TYRA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #272 out of 1411 companies for EV-to-OCF. This places Rapport Therapeutics in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Rapport Therapeutics's current EV-to-OCF is -18.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current EV-to-OCF of -18.77. The current EV-to-OCF is -18.77. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current EV-to-OCF is -18.77 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
